Press Releases
ImmunoGen, Inc. Announces Positive Interim Results in Randomized Clinical Trial
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the reporting of positive interim clinical data with trastuzumab-DM1 (T-DM1) for first-line treatment of HER2+ metastatic breast cancer in a press release issued by the European...
Press Releases
AJ Precision Components to Exhibit at Interplas 2011
AJ Precision Components will be exhibiting at Interplas 2011 from 27 to 29 September. Come and visit us on stand A58 in hall 4 at the NEC Birmingham, UK.
Press Releases
APR and Labtec enter into exclusive License Agreement with Ferrer International
APR and its development partner Labtec have entered into an exclusive licensing agreement with the leading European pharmaceutical company Ferrer Internacional (Ferrer) for the promotion, distribution and marketing of Donepezil Oral Dispersible Film (ODF) in Spain, Portugal and Germany....
Press Releases
Baxter Receives Approval For PREFLUCEL Seasonal Influenza Vaccine In Austria
Baxter International Inc. announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults...
Press Releases
Baxter Receives Approval For PREFLUCEL Seasonal Influenza Vaccine In Austria
Baxter International Inc. announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults...
Press Releases
Johnson & Johnson Completes Acquisition of Micrus Endovascular
Johnson & Johnson announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke. Johnson & Johnson announced its agreement to acquire Micrus on July 12,...
Press Releases
BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes
AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorisation application for BRILIQUE™ (ticagrelor) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS)....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
